Neuroanatomical characterisation of the expression of the lipodystrophy and motor-neuropathy gene Bscl2 in adult mouse brain by Garfield, Alastair S et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Neuroanatomical characterisation of the expression of the
lipodystrophy and motor-neuropathy gene Bscl2 in adult mouse
brain
Citation for published version:
Garfield, AS, Chan, WS, Dennis, RJ, Ito, D, Heisler, LK & Rochford, JJ 2012, 'Neuroanatomical
characterisation of the expression of the lipodystrophy and motor-neuropathy gene Bscl2 in adult mouse
brain' PLoS One, vol. 7, no. 9, pp. e45790. DOI: 10.1371/journal.pone.0045790
Digital Object Identifier (DOI):
10.1371/journal.pone.0045790
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
PLoS One
Publisher Rights Statement:
Copyright: © Garfield et al. This is an open-access article distributed under the terms of the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
Neuroanatomical Characterisation of the Expression of
the Lipodystrophy and Motor-Neuropathy Gene Bscl2 in
Adult Mouse Brain
Alastair S. Garfield1, Wai S. Chan1, Rowena J. Dennis2, Daisuke Ito3, Lora K. Heisler1*, Justin J. Rochford2
1Department of Pharmacology, University of Cambridge, Cambridge, United Kingdom, 2University of Cambridge Metabolic Research Laboratories, Institute of Metabolic
Science, Addenbrooke’s Hospital, Cambridge, United Kingdom, 3Department of Neurology, School of Medicine, Keio University, Shinjuku-ku, Tokyo, Japan
Abstract
The endoplasmic reticulum localised protein seipin, encoded by the gene Berardinelli–Seip congenital lipodystrophy type 2
(BSCL2), serves a critical but poorly defined function in the physiology of both adipose and neural tissue. In humans, BSCL2
loss-of-function mutations cause a severe form of lipodystrophy, whilst a distinct set of gain-of-toxic-function mutations are
associated with a heterogeneous group of neuropathies. However, despite the importance of seipin dysfunction to the
pathophysiology of these conditions, little is known about its physiological role in adipocytes or neurons. BSCL2 mRNA has
previously been identified in human and mouse brain, yet no definitive assessment of its expression has been undertaken.
Here we comprehensively characterised the neuroanatomical distribution of mouse Bscl2 using complementary in situ
hybridisation histochemistry and immunohistochemistry techniques. Whilst Bscl2 was broadly expressed throughout the
rostral-caudal extent of the mouse brain, it exhibited a discrete neuroanatomical profile. Bscl2 was most abundantly
expressed in the hypothalamus and in particular regions associated with the regulation of energy balance including, the
paraventricular, ventromedial, arcuate and dorsomedial nuclei. Bscl2 expression was also identified within the brainstem
dorsal vagal complex, which together with the paraventricular nucleus of the hypothalamus represented the site of highest
expression. Further neurochemical profiling of these two nuclei revealed Bscl2/seipin expression within energy balance
related neuronal populations. Specifically, seipin was detected in oxytocin neurons of the paraventricular nucleus of the
hypothalamus and in catecholamine neurons of the dorsal vagal complex. These data raise the possibility that in addition to
its role in adipose tissue development, seipin may also be involved in the central regulation of energy balance.
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Introduction
The resident endoplasmic reticulum protein, seipin, encoded by
the BSCL2 gene, has been implicated in both metabolic and
neurological disease. These distinct and non-overlapping condi-
tions appear to arise as a consequence of loss- and gain-of-function
BSCL2 mutations respectively, yet specific cellular functions for
seipin remain poorly defined [1–4].
BSCL2 was originally identified in a genetic screen of patients
suffering from a severe syndrome of congenital generalised
lipodystrophy (Berardinelli–Seip congenital lipodystrophy type 2)
with autosomal recessive inheritance [5]. In these cases a range of
point, premature stop, deletion or frameshift mutations in BSCL2
are likely to cause a loss of seipin function and lead to an almost
complete absence of adipose tissue [5–8]. Such congenital
lipodystrophy results in the development of a complex metabolic
syndrome characterised by severe insulin resistance, hyperlipidae-
mia and ectopic lipid storage [4]. Several laboratories have now
demonstrated critical roles for seipin in adipocyte differentiation
and adipose tissue development, implying that seipin disruption
causes lipodystrophy largely through a cell-autonomous defect of
adipogenesis [9–12]. A distinct set of pathogenic gain-of-toxic
function mutations in BSCL2 have been shown to cause a clinically
heterogeneous class of autosomal dominant motor neuropathy
syndromes, collectively termed the seipinopathies [3,13]. BSCL2
point mutations that affect an N-glycosylation site at amino acid
88 (N88S or S90L) result in aggregation of the mutant seipin
protein and the proposed pathogenic activation of ER stress
pathways [3,13,14]. These seipinopathies exhibit broad pheno-
typic variance across patients but are ultimately defined by upper,
lower and/or peripheral motor neuron disturbance but no
apparent metabolic symptoms. Importantly, murine modelling of
BSCL2 pathologies reveals significant functional conservation
between humans and mice, such that whilst Bscl2 ablation leads
to lipodystrophy [15] the overexpression of an N88S mutant
transgene promotes progressive motor deficits [16].
The involvement of BSCL2 in lipodystrophy and neuropathy is
associated with its expression in adipocytes and spinal cord motor
neurons respectively. In addition, the reported roles of seipin in
lipid droplet morphology and/or biogenesis in multiple cell types
and model organisms also indicate roles in normal cellular
function [1,9,11,12,17,18]. In this regard, the presence of BSCL2
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expression in a range of other human tissue types including brain,
liver, kidney, pancreas and testis also warrants further investigation
[13].
Here we provide the first comprehensive neuroanatomical
analysis of mouse brain Bscl2 expression. We report that Bscl2 is
expressed in numerous specific structures throughout the brain.
We find that Bscl2 mRNA exhibits a highly defined neuroana-
tomical profile and that its expression is strongly associated with
nuclei implicated in the regulation of energy balance.
Materials and Methods
Animals
Male C57BL/6 or mice on a C57BL/6 background expressing
enhanced green fluorescent protein (EGFP) under the control of
POMC regulatory elements (POMC-EGFP mice; generous gift
from Prof. Richard Simerly, University of Southern California and
Prof. Malcolm Low, University of Michigan [19]) between the
ages of 2–4 months were provided with standard laboratory chow
and water ad libitum and maintained in a light (12 h on/12 h off)
and temperature controlled environment (21.5–22.5uC). All
experiments were carried out in accordance with the U.K.
Animals (Scientific Procedures) Act 1986, with appropriate ethical
approval.
Tissue Preparation
Mice were deeply anesthetised with pentobarbitone (50 mg/kg
i.p.) and transcardially perfused with diethylpyrocarbonate
(DEPC)-treated phosphate buffered saline (PBS) followed by
10% neutral buffered formalin (Sigma). Following extraction,
brains were post fixed overnight in 10% neutral buffered formalin
and then transferred to 20% sucrose for cryoprotection. Brains
were sectioned on a freezing sliding microtome at 25 mm and
collected in five equal series of adjacent tissue.
Bscl2 Riboprobe Synthesis
A Bscl2 specific riboprobe complementary to exon 7–12 of the
mouse coding region (NM_001136064) was generated by PCR
using cDNA obtained from mouse brain and the product cloned
into a pCR2II-TOPO vector (Invitrogen). The recombinant
plasmid was linearized by restriction digest and subject to in vitro
transcription with a T7 (antisense) or SP6 (sense) RNA polymerase
in the presence of 35S-labelled UTP (for radioactive in situ
hybridisation) or digoxigenin-labelled UTP (for fluorescent in situ
hybridisation histochemistry) according to the manufacturer’s
instructions (Ambion).
Radioactive in situ Hybridisation Histochemistry (ISHH)
Sectioned brain tissue was processed for ISHH as previously
described [14]. 35S-labeled Bscl2 riboprobe was diluted to
26107 cpm ml21 in a hybridization buffer composed of 50%
formamide, 20 mM Tris-HCl pH 7.5, 0.02% sheared single-
stranded DNA (Sigma), 0.1% total yeast RNA (Sigma), 0.01%
yeast tRNA (Gibco), 20% dextran sulphate, 0.3 M NaCl, 2 mM
EDTA pH 8.0, Denhardt’s solution (Sigma), 100 mM DTT, 0.2%
SDS and 0.2% sodium thiosulphate (Sigma). Brain sections were
mounted onto superfrost slides and allowed to air dry. Sections
were fixed in 4% formaldehyde in DEPC-treated PBS for 20 min
at 4uC, dehydrated in ascending concentrations of ethanol, cleared
in xylene for 15 min, rehydrated in descending concentrations of
ethanol and permeabilised by heating in sodium citrate buffer (95–
100uC, pH 6.0), before being dehydrated in ascending concen-
trations of ethanol, and air-dried. Hybridization solution (contain-
ing radiolabelled riboprobe) and a coverslip were applied to each
slide, and sections were incubated for 16 hrs at 57uC. Coverslips
were then removed, and slides were washed with 26 sodium
chloride/sodium citrate buffer (SSC). Sections were incubated in
0.002% RNase A (Qiagen) for 30 min, followed by sequential
washes in decreasing concentrations of SSC. Sections were
dehydrated in ascending concentrations of ethanol with 0.3 M
ammonium acetate (NH4OAc) followed by 100% ethanol. Slides
were air-dried and placed in X-ray film cassettes with BMR-2 film
(Kodak) for 72 hrs. Films were developed on an OPTIMAX X-ray
film processor (Protec). Slides were subsequently dipped in
photographic emulsion (GE Healthcare) and stored at 4uC for
2 wks before being developed in D-19 developer and fixer
(Kodak). Slides were imaged under darkfield microscopy.
Dual-fluorescent in situ Hybridisation and
Immunofluorescent Histochemistry
A digoxigenin-labelled Bscl2 riboprobe was diluted 1/200 in the
hybridisation buffer described above. Brain tissue mounted onto
superfrost slides was fixed in 4% formaldehyde in DEPC-treated
PBS for 20 min at 4uC, dehydrated in ascending concentrations of
ethanol, cleared in xylene for 15 min, rehydrated in descending
concentrations of ethanol and permeabilised by heating in sodium
citrate buffer (95–100uC, pH 6.0), before being dehydrated in
ascending concentrations of ethanol, and air-dried. Hybridization
solution (containing digoxigenin-labelled Bscl2 riboprobe) and a
coverslip were applied to each slide, and sections were incubated
for 16 hrs at 57uC. Tissue was then processed for fluorescent in
situ hybridisation. Briefly, following washing in decreasing
concentrations of SSC, slides were rinsed in TNT buffer (0.1 M
TRIS-HCL pH 7.5, 0.15 M NaCl, 0.3% Triton-X-100) and
blocked for 30 min in TNB buffer (0.1 M TRIS-HCL pH 7.5,
0.15 M NaCl, 0.5% blocking reagent) at room temperature in a
humidified chamber. Sections were then incubated in a horserad-
ish peroxidase conjugated anti-digoxigenin antibody (Roche)
diluted 1/100 in TNB buffer. Following a series of TNT washes
slides were treated with tyramide signal amplification (TSA) biotin
plus kit, as per manufactures instructions (PerkinElmer). Probe
detection was achieved using an anti-streptavidin 594 antibody
diluted 1/250 in TNB buffer at room temperature for 30 min.
After extensive washing in PBS slides were processed for
immunofluorescent histochemical detection of seipin. Slides were
incubated in blocking buffer containing 0.5% BSA, 0.5% Triton-
X 100 in PBS for 1 hr at room temperature and then incubated
overnight at room temperature in blocking buffer containing
rabbit anti-seipin antibody (1/1000; [20]). Sections were subse-
quently washed in PBS followed by incubation with a donkey anti-
rabbit 488 antibody (1/1000 in blocking buffer, Alexa Fluor,
Molecular Probes) for 1 hr at room temperature. Slides were
washed in PBS and cover-slipped in an aqueous mounting
medium (Vectastain; Vector Laboratories).
Immunofluorescent Histochemistry
Free floating sections were washed in PBS, incubated in
blocking buffer (0.5% BSA, 0.5% Triton-X 100 in PBS) for 1 hr
and then incubated overnight in blocking buffer containing rabbit
anti-seipin antibody (1/1000). Sections were subsequently washed
in PBS followed by incubation with a donkey anti-rabbit 568
antibody (1/1000 in blocking buffer, Alexa Fluor, Molecular
Probes) for 1 hr. Sections were then washed in PBS, incubated in
blocking buffer and incubated overnight with one of the following
primary antibodies: rabbit anti-oxytocin (1/1000, Phoenix Phar-
maceuticals), mouse anti-tyrosine hydroxylase (1/1000, Chemi-
con) or goat anti-green fluorescent protein (1/1000, Abcam).
Sections were subsequently washed in PBS followed by 1 hr
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incubation in blocking buffer containing appropriate secondary
antibody (1/1000; 488 Alexa Fluor, Molecular Probes). Sections
were rinsed in PBS, mounted onto glass microscope slides and
cover-slipped in an aqueous mounting medium (Vectastain;
Vector Laboratories).
Imaging and Analysis
Slides were viewed on a Zeiss Axioskop 2 fluorescent
microscope and images captured using Zeiss AxioCam HRc
digital camera and AxioVision software. Fluorescent images were
merged using Adobe Photoshop CS3. Double labelled cells were
recorded if both fluorescent signals were present in the same cell
and each alone clearly defined a cellular shape.
Results
Neuroanatomical Distribution of Mouse Bscl2 mRNA
Expression of brain Bscl2 mRNA across the rostral-caudal
extent of the mouse brain was investigated using a Bscl2 specific
riboprobe (corresponding to exon 7–12 of the mouse Bscl2 coding
region, Fig. 1A–C) and radioactive ISHH. Gross saggital section
analysis revealed extensive but discrete Bscl2 expression through-
out the mouse neuraxis with robust expression detected in the
basal forebrain at the level of the preoptic area, the hypothalamus
and dorsal and ventral aspects of the brainstem (Fig. 1B). More
neuroanatomically refined assessment of Bscl2 mRNA distribution
demonstrated a broad but region specific profile (Fig. 2 and
Table 1).
The cerebral cortex exhibited a consistent but relatively low
level of Bscl2 expression in all neuroanatomical domains. This
expression was moderately higher within the olfactory nuclei of the
cortex but robustly elevated in the piriform cortex (Pir; Fig. 2A).
Within the basal ganglia, expression was significantly lower; only
scattered cells were evident within the globus pallidus (although
the level of cellular expression was noticeably robust) and no
detectable expression was observed within the caudate putamen
(Fig. 2C). At the midline, Bscl2 mRNA expression was highest in
medial septal nucleus (MS; Fig. 2C, D) and extended ventrolat-
erally into the nucleus of the diagonal band (vertical and
horizontal) and magnocellular preoptic area (MCPO; Fig. 2D).
Expression within the lateral septal nucleus was predominantly
confined to the ventral domain (LSV; Fig. 2D). Low level
expression was found in the bed nucleus of the stria terminalis
but no significant signal was detected in the nucleus accumbens.
Bscl2 expression within the thalamus was generally low,
although the anterior paraventricular nucleus of the thalamus
(PVA; Fig. 2F) exhibited a significant level of Bscl2 mRNA, with
weaker expression detected at the posterior extent of the nucleus.
Expression was also evident within the central medial thalamic
nucleus, reticular thalamic nucleus and reuniens nucleus. Very
high levels of Bscl2 mRNA were detected in the medial habenular
nucleus (MHb; Fig. 2I) and, at the thalamic/hypothalamic
boundary, within the zona incerta (ZI; Fig. 2H) and subincertal
nucleus. Expression within the hippocampus (Fig. 2I) was
restricted to the granular layer of the dentate gyrus (GrDG) and
the pyramidal cell layer (Py) and strikingly high in both structures.
The hypothalamus represented the highest concentration of
Bscl2 mRNA within the adult mouse brain (Fig. 2G–I). At the
anterior extreme, Bscl2 was robustly expressed within preoptic
area (Fig. 2D, E); in particular the median preoptic nucleus (all
Figure 1. Expression of Bscl2 mRNA in adult mouse brain. Autoradiographical visualisation of Bscl2 mRNA in saggital section of the adult
mouse brain using radioactive in situ hybridisation histochemistry. (A) Diagrammatic representation of the mouse Bscl2 locus detailing the location of
the ISHH riboprobe (not to scale). (B) Endogenous Bscl2 expression as detected by a specific antisense riboprobe revealed strong expression within
the basal forebrain (BF), hippocampus (Hippo), hypothalamus (Hypo), dorsal brainstem (dBS) and ventral brainstem (vBS). (C) Corresponding Bscl2
sense riboprobe control.
doi:10.1371/journal.pone.0045790.g001
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Table 1. Distribution of Bscl2 mRNA in the mouse central
nervous system.
Cerebral cortex
Cingulate cortex +
Motor cortex +
Primary somatosensory cortex +
Visual cortex +
Orbital cortex +
Indusium griseum ++
Olfactory nucleus ++
Olfactory turbcle +
Piriform cortex ++++
Striatum
Globus pallidus, lateral SC (++)
Globus pallidus, medial SC (++)
Ventral pallidum +
Hippocampus and septum
Dentate gyrus, granular layer ++
Island of Calleja ++
Lateral septal nucleus, ventral ++
Lateral septal nucleus, dorsal +
Medial septal nucleus +++
Nucleus of the limb diagonal band, ventral ++
Nucleus of the limb diagonal band, horizontal ++
Magnocellular preoptic nucleus ++
Pyramidal cell layer of hippocampus ++++
Septohippocampal nucleus ++
Subfornical organ +++
Bed nucleus of the stria terminalis, medial div +
Bed nucleus of the stria terminalis, lateral div +
Amygdala
Basolateral amygdaloid nucleus, anterior +++
Central amygdaloid nucleus ++
Medial amygdaloid nucleus, posterodorsal +++
Medial amygdaloid nucleus, posteroventral ++
Thalamus
Anterior thalamic nucleus +
Central medial thalamic nucleus ++
Paraventricular thalamic nucleus anterior ++
Lateral habenular +
Medial habenular ++++
Subparafascicular thalamic nucleus SC (++)
Reticular thalamic nucleus +++
Reuniens nucleus ++
Zona incerta ++++
Subincertal nucleus ++++
Hypothalamus
Acruate nucleus ++++
Anterior hypothalamic nucleus ++
Dorsomedial nucleus, mediodorsal +++
Dorsomedial nucleus, central +++
Dorsomedial nuzcleus, medioventral +++
Lateral hypothalamic area SC (++)
Lateral mammillary nucleus ++
Lateral preoptic area +++
Medial mammillary nucleus +
Median preoptic nucleus ++++
Median preoptic nucleus, medial ++++
Median preoptic nucleus, lateral ++++
Medial preoptic area +++
Paraventricular nucleus, ventral +++++
Paraventricular nucleus, lateral magnocellular +++++
Paraventricular nucleus, medial magnocellular +++++
Paraventricular nucleus, anterior parvicellular SC (++)
Paraventricular nucleus, medial parvicellular SC (+)
Paraventricular nucleus, posterior +++
Posterior hypothalamus +++
Premammillary nucleus, dorsal ++
Premammillary nucleus, ventral +++
Subthalamic nucleus SC (+)
Suprachiasmatic nucleus +++
Supraoptic nucleus +++++
Supramammillary nucleus, medial ++
Ventromedial nucleus, central ++
Ventromedial nucleus, dorsomedial +++
Ventromedial nucleus, ventrolateral +++
Ventromedial preoptic nucleus +++
Midbrain and Pons
Barrington’s nucleus +++
Caudal linear nucleus of raphe ++
Central gray of the pons +
Dorsal raphe nucleus +++
Dorsal tegmental area +++
Edinger-Westphal nucleus +++++
Lateral parabrachial nucleus ++
Lateral reticular nucleus
Laterodorsal tegmental area +++
Laterodorsal tegmental nucleus ++
Locus coeruleus ++++
Medial parabrachial nucleus SC (+)
Median Raphe +++
Nucleus of Darkschewitch +++
Periaqueductal Grey +
Parabigeminal nucleus +
Pontine nuclei +++
Pontine nucleus, oral part SC (++)
Pontine reticular nucleus, caudal part SC (+)
Principal sensory trigeminal nucleus SC (+)
Red nucleus SC (++)
Reticulotegmental area SC (++)
Reticulotegmental nucleus of the pons ++
Substantia nigra pars compacta ++
Superior colliculus +
Table 1. Cont.
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domains) and to a lesser extent the ventromedial preoptic nucleus
(VMPO) and median preoptic area (MPA). In general, Bscl2
expression extended uniformly though the extent of each relevant
nucleus. The paraventricular nucleus of the hypothalamus (PVN;
Fig. 2G) was the most abundant site of Bscl2 expression within the
brain. Bscl2 mRNA within the PVN was robustly expressed in the
ventral (Fig. 3A), magnocellular (medial and lateral portions;
Fig. 3B) and posterior domains (Fig. 3C). Scattered expression was
evident within the anterior parvicellular (Fig. 3A) nucleus and to a
lesser extent the medial parvicellular region (Fig. 3B). The
supraoptic nucleus (SO; Fig. 2F) also demonstrated very high
levels of Bscl2 mRNA. Lower levels were detected within the
anterior, dorsomedial (DMH), arcuate (ARC) and posterior
hypothalamic (PH) nuclei (,2H). The lateral hypothalamus (LH)
contained only scattered cells. The ventromedial hypothalamus
(VMN) exhibited regional variance in Bscl2 expression with the
central portion demonstrating lower levels than that observed in
the dorsomedial and ventrolateral domains (Fig. 2H). Within more
caudal regions, Bscl2 was detected in the ventral and dorsal
premammillary nucleus and the central supramammillary nucleus
(SuMM; Fig. 2I).
Within the midbrain, moderate Bscl2 expression was apparent
in the subsantia nigra pars compacta (SnC) and adjacent ventral
tegmental area (VTA; Fig. 2J), but not the subsantia nigra pars
reticulata. At the level of the cerebral aqueduct, two sites of robust
expression were identified as the Edinger-Westphal (EW) nucleus
and the nucleus of Darkschewitch (Dk; Fig. 2J). Caudal to this, low
level expression was detected in all regions of the periaqueductal
grey (PAG) and the superior colliculus. The dorsal raphe nucleus
(DRN) exhibited the greatest level of Bscl2 mRNA within the
raphe nuclei, with the dorsal portion containing the highest
expression (Fig. 2K). The median (MnR) and caudal linear raphe
demonstrated more uniform but moderate expression (Fig. 2K).
The brainstem raphe nuclei (magnus, obscurus and pallidus) were
typified by scattered Bscl2 containing cells. Within the pons, robust
expression was detected in the locus coeruleus (LC; Fig. 2M) and
to a lesser extent the lateral parabrachial nucleus (LPBN; Fig. 2L),
laterodorsal (LDTg) and dorsal tegmental nuclei (DTg; Fig. 2L).
Only the granular layer of the cerebellum was positive for Bscl2
expression.
Brainstem Bscl2 expression was evident within a number of
cranial nuclei, specifically, the abducens nucleus (6N), facial
nucleus (7N) and hypoglossal nucleus (12N). Very high expression
was detected in the ambiguous nucleus (Fig. 2N). Moderate
expression was detected in the medial vestibular nucleus (MVe)
lateral to the fourth ventricle (Fig. 2N). The dorsal vagal complex
(DVC), comprised of the nucleus of the solitary tract (NTS), the
dorsal motor nucleus of the vagus (10N) and area postrema,
exhibited robust expression that was highest in the 10N at the
subpostremal level (Fig. 2O and Fig. 3). No expression was
detected in the area postrema, whilst the NTS exhibited robust
Bscl2 signal within the medial and lateral domains (Fig. 3E and F).
Seipin Immunoreactivity within the PVN and DVC
The abundant expression of Bscl2 within energy balance
associated nuclei of the brain, together with its established
involvement in peripheral metabolism, prompted further investi-
gation of two central sites of robust Bscl2 expression, the PVN and
DVC. Validation of the seipin antibody (SCT14) for subsequent
neurochemical profiling was undertaken using fluorescent ISHH
for Bscl2 combined with fluorescent immunohistochemistry for
seipin (Fig. 4). Dual labelling for Bscl2 and seipin in the PVN was
evident in the vast majority of cells at all levels of the nucleus
(Fig. 4A–C) and was absent in negative controls (Fig. 4D–F).
Similar results were obtained within the DVC (Fig. 4G–L).
Neurochemical Profiling of Seipin Expressing Cells in the
PVN and DVC
The cellular heterogeneity of the PVN and DVC raised
questions as to the neurochemical nature of seipin expressing
cells. Dual immunofluorescent co-localisation of seipin with
markers for PVN neuronal populations indicated that oxytocin
cells of both the parvicellular and magnocellular portions were
positive for seipin expression (Fig. 5A–C). However, catechol-
amine neurons (as labelled by tyrosine hydroxylase (TH)
immunoreactivity) of the ventral PVN were seipin negative
(Fig. 5D–F). In the DVC, seipin was co-expressed with TH
(Fig. 6A–C), but not pro-opiomelanocortin (POMC) neurons (as
labelled by GFP in a transgenic POMC-EGFP line) (Fig. 6D–F). In
contrast, a subpopulation of hypothalamic POMC neurons did co-
express seipin (data not shown).
Discussion
Despite the lack of a precisely defined cellular function,
appropriate expression of wild-type Bscl2 is critical to the
development and physiology of both adipose and neural tissue.
Unsurprisingly, the role of seipin in the manifestation of
lipodystrophy and motor neuropathy has dominated much of
the current research. However, in light of such a strong
pathological association, evidence of Bscl2 expression in numerous
other tissues also warrants further investigation.
Previous analysis of central BSCL2 expression in human brain
utilised northern blotting of macro-dissected tissue homogenates.
These findings indicated seemingly ubiquitous BSCL2 expression
in the cerebellum, cerebral cortex, frontal, temporal and occipital
lobes, and to a lesser extent the medulla and caudate putamen
[13]. No detailed analysis of Bscl2 mRNA distribution in mouse
Table 1. Cont.
Ventral tegmental area ++
Ventral tegmental nucleus ++
Cerebellum
Granular layer +
Medulla
Abducens nucleus SC (++)
Ambiguous nucleus +++++
Dorsal motor nucleus of the vagus +++
Facial nucleus SC (++)
Gigantocellular reticular nucleus SC (+)
Hypoglossal nucleus +++
Medial vestibular nucleus ++
Nucleus of the solitary tract, medial +++
Nucleus of the solitary tract, lateral +++
Raphe Magnus + SC
Raphe Obscurus + SC
Raphe Pallidus + SC
Qualitative assessment of Bscl2 mRNA expression across the rostral-caudal
extent of the adult mouse brain, as indicated by radioactive in situ hybridisation
histochemistry. Levels of expression: +, very low; ++, low; +++, moderate; ++++,
high; +++++, very high; SC (+), scattered cells of low expression; SC (++)
scattered cells of high expression.
doi:10.1371/journal.pone.0045790.t001
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Figure 2. Neuroanatomical characterisation of Bscl2 mRNA in adult mouse brain. Radioactive in situ hybridisation histochemistry analysis
of Bscl2 mRNA distribution in coronal section across the rostral-caudal extent of adult mouse brain. Endogenous Bscl2 expression was detected
throughout the brain, for full characterisation see Table 1. (A–O) 35S-labelled Bscl2 expression was detected in the piriform cortex (Pir), olfactory
tubercle (Tu), islands of Calleja (ICj), caudate putamen (CP) lateral septal nucleus intermediate part (LSI), medial septal nucleus (MS), nucleus of the
vertical limb of the diagonal band (VDB), lateral septal nucleus ventral part (LSV), nucleus of the horizontal limb of the diagonal band (HDB),
magnocellular preoptic nucleus (MCPO), ventromedial preoptic nucleus (VMPO), median preoptic nucleus (MnPO), medial preoptic nucleus medial
part (MPOM), paraventricular thalamic nucleus (PVA), lateral globus pallidus (LGP), supraoptic nucleus (SO), suprachiasmatic nucleus (SCh), subfornical
organ (SFO), paraventricular nucleus of the hypothalamus (PVN), zona incerta (ZI), dorsomedial nucleus of the hypothalamus (DMH), ventromedial
nucleus of the hypothalamus (VMH), arcuate nucleus of the hypothalamus (ARC), basomedial amygdaloid nucleus (BMA), medial amygdaloid nucleus
(MeA), medial habenular (MHb), pyramidal cell layer of the hippocampus (py), granular layer of the dentate gyrus (GrDG), posterior hypothalamus
(PH), supramammilliary nucleus medial part (SuMM), premammillary nucleus ventral part (PMV), nucleus of Darkschewitsch (Dk), Edinger-Westphal
nucleus (EW), ventral tegmental area (VTA), dorsal raphe nucleus (DRN), periaqueductal grey (PAG), median raphe nucleus (MnR), lateral parabrachial
nucleus (LPBN), dorsal tegmental nucleus (DTg), laterodorsal tegmental nucleus (LDTg), locus coeruleus (LC), Barrington’s nucleus (Bar), medial
vestibular nucleus (MVe), ambiguous nucleus (Amb), dorsal vagal complex (DVC), hypoglossal nucleus (12N). Scale bar in (A) represents 1 mm and
applies to all other images.
doi:10.1371/journal.pone.0045790.g002
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brain has been reported, although its presence in whole brain
samples has been demonstrated by RT-PCR [13]. Our combined
utilisation of in situ hybridisation histochemistry (for Bscl2 mRNA)
and immunohistochemistry (for seipin protein) now provides
insight into the specific neuroanatomical distribution of mouse
Bscl2/seipin.
The breadth of Bscl2 expression observed in the mouse is
consistent with that previously reported of the human brain.
Specifically we identified mRNA expression at all levels of the
brain, with a more refined profile evident within the hypothalamus
and brainstem. A first set of seipin-expressing regions directly
concerns motor control, which is in keeping with the major
phenotypic trait of seipinopathies. Interestingly, contrary to
human data we find no evidence of Bscl2 expression in the
caudate putamen [13], although scattered expression was appar-
ent in the globus pallidus. The expression of Bscl2 within the motor
cortex may be of relevance to Silver Syndrome, a seipinopathy
characterised in part by upper motor neuropathy [3]. Indeed,
motor impairment in N88S mutant mice is correlated with mutant
seipin aggregates in the motor cortex neurons [16]. Furthermore,
Bscl2 is robustly expressed in the ambiguous nucleus (XI cranial
nerve) of the rostral medulla, the source of efferent motor fibres to
Figure 3. Bscl2 mRNA distribution within the PVN and DVC. Radioactive in situ hybridisation histochemistry analysis of Bscl2 mRNA
distribution in coronal section across three rostral-to-caudal levels of adult PVN and DVC. (A–C) 35S-labelled Bscl2 mRNA expression in the PVN
demonstrating robust labelling in the ventral (A), medial magnocellular (B), lateral magnocellular (B, C) and posterior domains (C). Scattered Bscl2
labelled cells were expressed in the anterior and medial (B, C) parvicellular portion. (D–F) 35S-labelled Bslc2 mRNA expression in the DVC was highest
within the 10N at the level of the area postrema. Within the NTS the preponderance of Bscl2 mRNA was localised to the medial and ventral domains
(E, F). No expression was detected in the area postrema (E). 4v, fourth ventricle; 10N, dorsal motor nucleus of the vagus; 12N, hypoglossal nucleus; AP,
area postrema; cc, central canal; PaAP, PVN anterior parvicellular; PaLM, PVN lateral magnocellular; PaMM, PVN medial magnocellular; PaMP, PVN
medial parvicellular; PaPo, PVN posterior; PaV, PVN ventral; SolC, NTS commissural; SolDL, NTS dorsolateral; SolG, NTS gelatinous; SolIM, NTS
intermediate; SolM, NTS medial; SolV, NTS ventral; SolVL, NTS ventrolateral.
doi:10.1371/journal.pone.0045790.g003
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the muscles groups of the shoulder and neck, and may be
associated with the upper body weakness (in particular the
shoulders) observed in Silver Syndrome patients [3]. The
presentation of ocular defects in some seipinopathies [21] seems
unlikely to be associated with disruption of cranial nerve
innervation of the eye, as Bscl2 expression was not detected in
the optic (2N), occulomotor (3N) or trochlear (4N) nuclei.
BSCL2 loss-of-function mutations underlie the congenital
generalised lipodystrophy BSCL2, characterised by a near
complete absence of adipose tissue and associated metabolic
dysregulation. Some BSCL2 patients have also been reported to
display cognitive impairment [6]. Although this aspect of the
phenotype is less clear than that affecting adipose tissue, it remains
possible that central BSCL2 expression is of importance to
neurodevelopment and cognition.
Robust Bslc2 expression was also detected in neural structures
concerned with the regulation of energy balance, namely the
hypothalamus and brainstem (DVC). The cross-talk between the
brain and adipose tissue is clearly central to the regulation of body
weight with both hormonal and neurological connections between
these two tissues providing bidirectional modulation of their
respective functions [22,23]. For example, the level of the
adipostatic hormone leptin rises with fat accrual and acts directly
within the brain to communicate long-term nutritional fitness and
short term appetitive state, leading to centrally mediated activation
of appropriate physiological and behavioural responses [24].
Equally, sympathetic innervation of fat enables central control of
lipid metabolism and thus energy storage [25]. Interestingly, a
number of genes highly expressed in the adipocyte are also found
in the brain, and particularly the hypothalamus, suggesting a level
of functional convergence. The hypothalamus represents the most
abundant site of Bscl2 mRNA in the mouse brain, implying a
potential involvement in homeostatic aspects of physiology and
behaviour. In this regard, it is of note that robust Bscl2 expression
was detected in a number of hypothalamic nuclei intimately
associated with the regulation of energy homeostasis and body
weight, specifically, the paraventricular, arcuate, ventromedial and
dorsomedial nuclei. Bscl2 expression was also identified within the
DVC, a brainstem nucleus comprised of specific sub-nuclei with
an implicit involvement in the energy balance, including the NTS
which serves as a integrative node through which numerous
peripheral appetitive cues are routed and the 10N that provides
direct neural innervation and regulation of peripheral tissues,
(including adipose tissue, liver and intestine/stomach) and is a
target for the actions of peripheral appetitive cues such as leptin
and cholecytokinin [26]. Moreover, the PVN and DVC represent
the sites of highest Bscl2 expression in the mouse brain.
Neurochemical profiling of seipin-immunoreactive neurons
within the PVN and DVC identified its expression in oxytocin
and catecholaminergic neurons, respectively. Both these popula-
tions are associated with the regulation of energy balance [27,28].
Seipin expression within the PVN was predominantly localised to
Figure 4. Validation of seipin antibody in the PVN and DVC of adult mouse. Dual Bscl2 fluorescent in situ hybridisation and seipin
immunohistochemistry. (A–C) Co-localisation of Bscl2 mRNA and seipin in the magnocellular domain of the paraventricular nucleus of the
hypothalamus (PVN) and (G–I) dorsal vagal complex (DVC). Co-localisation denoted by yellow colouring in panels C and I. Negative controls for
fluorescent in situ hybridisation and immunohistochemical protocols in the PVN (D–F) and DVC (J–L) revealed no non-specific staining. Inserts (C9)
and (I9) show high magnification images of cellular co-localisation. Scale bar in (A) represents 25 mm and applies to figures A–L; scale bar in (C9)
represents 10 mm and applies to I9.3v, third ventricle; cc, central canal.
doi:10.1371/journal.pone.0045790.g004
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Figure 6. Neurochemical profile of seipin positive neurons in the DVC of adult mouse. Dual immunofluorescent co-localisation of seipin
and (A–C) tyrosine hydroxylase (TH) and (D–E) green fluorescent protein under the control of the pro-opiomelanocortin promoter (POMC-EGFP) in
the nucleus of the solitary tract (NTS). Co-localisation with TH was evident within NTS (as denoted by yellow colouring in panel C and C9). No co-
localisation was observed with GFP. Scale bar in (A) represents 25 mm and applies to figures A-E; scale bar in (C9) represents 10 mm. 3v, third ventricle.
cc, central canal.
doi:10.1371/journal.pone.0045790.g006
Figure 5. Neurochemical profile of seipin positive neurons in the PVN of adult mouse. Dual immunofluorescent colocalisation of seipin
and (A–C) oxytocin (Oxy) and (D–E) tyrosine hydroxylase (TH) in the paraventricular nucleus of the hypothalamus (PVN). Colocalisation with oxytocin
was evident within PVN (as denoted by yellow colouring in panel C and C9). No colocalisation was observed with TH. Scale bar in (A) represents 25 mm
and applies to figures A–E; scale bar in (C9) represents 10 mm. 3v, third ventricle.
doi:10.1371/journal.pone.0045790.g005
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the magnocellular domains, with only scattered cells identified in
the parvicellular regions. Oxytocin neurons in the mouse exhibit a
similar neuroanatomical profile such that they are predominantly
localised to the magnocellular PVN with far fewer cells evident in
the parvicellular PVN. Our colocalisation studies indicate that in
both regions seipin colocalised with oxytocin. Although studies in
rats have identified a functional divergence of magnocellular
versus parvicellular PVN oxytocin neurons, with the former being
associated with the neuroendocrine control of lactation, parturi-
tion and osmoregularity and the latter implicated in the regulation
of feeding, the situation in the mouse is less clear. Importantly,
there is a distinct paucity of oxytocin expressing neurons within the
parvicellular region of mice as compared to the rat, as well as
significant differences in the neuroarchitecture of the mouse and
rat PVN [29,30]. Thus in the mouse the function divergence of
oxytocin neuron populations (neuroendocrine versus CNS pro-
jecting) may not be solely defined by their neuroanatomical
location. Nevertheless, the importance of oxytocin neurons to the
regulation of energy balance in the mouse is well established
[27,31] and provides circumstantial support for involvement of
seipin in this function (as well as other aspects of oxytocin
regulated physiology). Broad seipin-immunoreactivity within non-
oxytocin neurons of the magnocellular PVN illustrates its
expression in additional populations of cells that may include
corticotrophin-releasing hormone, vasopressin, somatostatin and
thyrotropin-releasing peptide. Seipin expression within the DVC
was identified in the A2 noradrenergic population of the NTS but
not in POMC-EGFP labelled cells. The A2 population is
implicated in the homeostatic regulation of cardiovascular reflex
and stress. These neurons are also associated with the regulation of
energy balance inasmuch as they are reactive to peripheral
appetitive cues including amylin [28] and an indirect target for
cholecytokinin [32] and ghrelin [33] (via the modulation of
glutamatergic vagal afferents). Interestingly, there is a significant
degree of reciprocal innervations between the PVN and DVC that
includes A2 neuron projection to the PVN [34] and oxytocin
neuron projection to the NTS [35]. Whether seipin expression in
these cells types is of functional relevance to this neuroanatomical
circuit remains to be investigated. That seipin was not identified
within catecholaminergic neurons of the PVN or POMC neurons
of the NTS (but was evident in POMC-EGFP neurons of the
ARC) suggests a degree of functional specificity that remains to be
clarified.
Whilst it is at present impossible to attribute these observations
with physiological function, the expression of Bscl2 in both fat and
energy balance associated brain regions raises the possibility that
seipin may serve to influence energy homeostasis at both the
peripheral and central level. Although BSCL2 patients exhibit
dramatically increased appetite and increased metabolic rate this
most likely reflects the profound lack of leptin due to the paucity of
adipose tissue [36]. Seipin deficient mice do not appear to exhibit
perturbed feeding behaviour [15] but it is possible that both the
age of the mice in the study, the nature of the analysis and/or the
severity of this mutant’s pathology may mask an as yet unidentified
energy balance phenotype. Interestingly, seipin deficient mice
exhibit a significant increase in body temperature despite a 40%
reduction in brown adipose tissue (BAT) [15]. Whilst a complete
assessment of this phenotype has not yet been undertaken, it is
possible that loss of seipin in the brain promotes a centrally
mediated increase in BAT metabolic activity.
The role of seipin in adipocyte development appears, in part, to
involve an ability to regulate the expression or function of the
adipocyte differentiation factor peroxisome proliferator-activated
receptor gamma (PPARc) [10,37]. Dominant negative PPARc
mutations in humans also result in lipodystrophy [38]. It is of note
that both these genes are also expressed in the brain and exhibit
overlapping regional expression profiles, including a number of
hypothalamic nuclei [39]. This offers the intriguing possibility that
seipin might regulate PPARc expression or function in the brain.
Recent studies of neuronal PPARc have highlighted its critical role
in the regulation of energy balance and suggest that the inhibition
of central PPARc expression protects against the hyperphagia and
reduced energy expenditure, and thus weight gain, associated with
high fat diet induced obesity [40]. Furthermore, whilst speculative,
hyperthermia in Bscl2 knockout mice could be associated with an
attenuation of PPARc function since neuronal specific PPARc
deficient mice exhibit an upregulation of thermogenic gene
expression [40]. In light of these observations and the severe
metabolic pathology associated with global Bscl2 deficiency, the
generation of a neuron-specific Bscl2 knockout line will be critical
to unravelling any potential contribution of this gene to the central
regulation of energy balance.
In summary, our analysis of central Bscl2 expression reveals a
refined and provocative neuroanatomical profile, with the
preponderance of expression localised to specific energy balance
related nuclei of the hypothalamus and brainstem. In light of the
established pathophysiological relevance of adipocyte seipin
expression in the regulation of energy storage, these data raise
the possibility that neuronal seipin expression may serve an as yet
unidentified role in the central regulation of energy homeostasis.
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